Vicarious Surgical Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Vicarious Surgical Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($50.18M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($63.22M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($71.07M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $5.16M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | ($35.21M) | Feb 15, 2023 |
| FY2020 | Dec 31, 2020 | ($9.46M) | May 24, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($50.03M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($66.56M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($80.67M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($80.08M) | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | ($38.22M) | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | ($12.99M) | Mar 31, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.58M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $67.72M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $119.86M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $140.29M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $181.68M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $17.79M | Mar 31, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.74M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $21.02M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $21.90M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $29.25M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $98.59M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $935.0K | Mar 31, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.84M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $46.70M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $97.97M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $111.05M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $83.09M | Mar 4, 2024 |
| FY2022 | Dec 31, 2020 | ($29.82M) | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | ($17.52M) | Mar 31, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Mar 4, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Mar 4, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.57M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $9.74M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $52.82M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $116.21M | Mar 4, 2024 |
| FY2022 | Dec 31, 2021 | $173.51M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $16.87M | Mar 31, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $2.00M | Mar 4, 2024 |
| FY2023 | Oct 31, 2020 | $3.50M | Mar 4, 2024 |